Hypoxia-driven Prostate Cancer Genomics (HYPROGEN) - Illuminating the Genomic Landscape of Hypoxia-driven Early Metastatic Prostate Cancer
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Primary outcome measure
研究概览
简要总结
Due to the rapid growth, tumour demand for oxygen is often higher than what can be delivered by the newly forming blood vessels. Tumour adaption to this imbalanced oxygen supply and demand (hypoxia) is associated with poor prognosis and genetic changes (genomic instability) that allow it to become more resistant to chemo- and radiotherapy. Patients with hypoxic tumours therefore die earlier. Limited information is available on hypoxia in newly diagnosed prostate cancer, especially to what degree hypoxia in the prostate tumour is associated with the presence of metastases to bones. The Hyprogen trial is a prospective, non-randomised, exploratory biopsy and imaging biomarker study recruiting 60 patients with prostate cancer to better establish the role of hypoxia in prostate cancer cells evolution and early metastatic spread.
详细描述
Arm 1 of this study will aim to determine the association between hypoxia in the primary tumour with the presence of skeletal metastases and aim to determine if hypoxia is also present in the metastatic sites themselves. Arm 2 will aim to determine the genetic changes associated with hypoxia in cancers that have not spread outside the prostate. Hypoxia presence will be determined by using a hypoxia identifying stain (by giving a patient a tablet of the stain to take orally) and by identifying genomic alterations that are associated with hypoxia. After taking the tablet of the hypoxia marker (Pimonidazole) patients in Arm 1 will receive both a biopsy of the prostate and of one or two of the bone metastases. The presence or not as well as the degree of hypoxia in both sites will be assessed. Patients in Arm 2 will receive pimonidazole prior to a planned radical prostatectomy and the heterogeneity of hypoxia related genetic change throughout the prostate will assessed. Arm 2 patients will undergo MRI hypoxia imaging to validate the detection of pimonidazole marked hypoxic regions with a non-invasive imaging method.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Male patients aged 18 years and older
- •Histologically proven adenocarcinoma of the prostate (≥cT2) or Highly suspected metastatic prostate cancer
- •PSA value of ≥ 20 ng/mL
- •Multiple lesions (≥ 5) suspicious of metastatic spread on routine imaging procedures with at least one amenable* to biopsy (cohort A) or oligometastatic bone disease (≥1 to ≤ 4) at routine bone scan with at least one lesion amenable* to biopsy (cohort B)
- •*e.g. safely to biopsy and expectably providing sufficient tissue yield World Health Organisation (WHO) performance status 0 to 2 with no deterioration over the previous 2 weeks and minimum life expectancy of 12 months
- •No prior local and/or systemic treatment for localised prostate cancer
- •Willing to donate cancer tissue samples for research purposes (bone metastasis and primary tumour)
排除标准
- •Involvement in the planning and/or conduct of the study (applies to staff at the study site)
- •Previous enrolment in the HYPROGEN study
- •As judged by the investigator, any evidence of severe or uncontrolled systemic disease (e.g. uncompensated respiratory, cardiac, hepatic or renal disease)
- •Evidence of any other significant clinical disorder or laboratory finding that made it undesirable for the patient to participate in the study
- •Any investigational agents or study drugs from a previous clinical study within 30 days of the first tissue collection
- •Prior treatment of localized prostate cancer including radiotherapy and/or androgen-deprivation therapy
- •Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements
- •Contra-indications to MRI (incl. pacemakers etc.)
- •Bone metastases in difficult to reach areas or areas which might be at risk for pathological fracture post biopsy as judged by biopsying radiologist / chief investigator
- •Increased risk of bleeding as a result of biopsy
- •History of bleeding disorders or thrombocytopenia (platelets <100/nL)
- •Concomitant treatment with anticoagulant therapy, e.g. warfarin/low molecular weight heparin or Anti-Xa-inhibitors and other NOACs, if temporary cessation medically not justifiable
- •Current urinary tract infection (UTI) or prostatitis
- •Inclusion Criteria:
- •Male patients aged 18 years and older cT¬2-T3 / cN0-N1 / cM0 Any Group Grade (GG) 2-5: this includes Gleason scores 3+4, 4+3, 4+4, 4+5, 5+3, 5+4, 5+
- •Histologically proven adenocarcinoma of the prostate
- •Undergoing radical prostatectomy as primary treatment for localised prostate cancer
- •World Health Organisation (WHO) performance status 0 to 2 with no deterioration over the previous 2 weeks and minimum life expectancy of 12 months
- •No prior local and/or systemic treatment for localised prostate cancer
- •Willing to donate cancer tissue samples for research purposes (any metastasis and primary tumour)
- •Exclusion criteria:
- •Involvement in the planning and/or conduct of the study (applies to staff at the study site)
- •As judged by the investigator, any evidence of severe or uncontrolled systemic disease (e.g. uncompensated respiratory, cardiac, hepatic or renal disease)
- •Any investigational agents or study drugs from a previous clinical study within 30 days of the first tissue collection
- •Prior treatment of localized prostate cancer including radiotherapy and/or androgen-deprivation therapy
- •Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements
- •Contra-indications to MRI (incl. pacemakers etc.)
研究组 & 干预措施
Arm 1
Arm 1 - De novo, treatment-naïve metastatic prostate cancer
干预措施: Optional non-IMP pimonidazole (Drug)
Arm 1
Arm 1 - De novo, treatment-naïve metastatic prostate cancer
干预措施: CT-guided Bone Biopsy (Diagnostic Test)
Arm 1
Arm 1 - De novo, treatment-naïve metastatic prostate cancer
干预措施: TRUS-guided Targeted Transperineal Prostate Biopsy (Diagnostic Test)
Arm 1
Arm 1 - De novo, treatment-naïve metastatic prostate cancer
干预措施: Whole-body MRI (Diagnostic Test)
Arm 1
Arm 1 - De novo, treatment-naïve metastatic prostate cancer
干预措施: Baseline bloods - for germline testing (Other)
Arm 1
Arm 1 - De novo, treatment-naïve metastatic prostate cancer
干预措施: Baseline bloods for CTCs and ct DNA taken at same time as baseline bloods in Arm 1 (Other)
Arm 1
Arm 1 - De novo, treatment-naïve metastatic prostate cancer
干预措施: Post-pimonidazole bloods for CTCs and ctDNA (Other)
Arm 2
Arm 2 - De novo, treatment- naïve localised prostate cancer planned for radical prostatectomy
干预措施: Optional non-IMP pimonidazole (Drug)
Arm 2
Arm 2 - De novo, treatment- naïve localised prostate cancer planned for radical prostatectomy
干预措施: Radical Prostatectomy (Procedure)
Arm 2
Arm 2 - De novo, treatment- naïve localised prostate cancer planned for radical prostatectomy
干预措施: Prostate MRI scans (Diagnostic Test)
Arm 2
Arm 2 - De novo, treatment- naïve localised prostate cancer planned for radical prostatectomy
干预措施: Baseline bloods - for germline testing (Other)
结局指标
主要结局
Primary outcome measure
时间窗: 24 months
To document the differential genomic aberrations and gene expressional alterations in hormone-naïve primary prostate cancers and paired skeletal metastases with respect to the presence or abscence of tissue hypoxia in the tumour samples.
次要结局
- Secondary outcome measure(24 months)